DPCO 2013: A fair move or a misstep?

The DPCO 2013 issued by the DOP covers the prices of 652 formulations in over 27 therapeutics. Usha Sharma talks to industry stalwarts to gauge their reactions on this move

Kiran Mazumdar Shaw, Chairman & Managing Director, Biocon

Tapan Ray, Director General, Organisation of Pharmaceutical Producers Of India (OPPI)

Daara B Patel, Secretary-General, Indian Drug Manufacturers Association

Ameesh Masurekar, Director, AIOCD Pharmasofttech AWACS

Amit Backliwal, Managing Director, IMS Health — South Asia

Subrata Ray, Senior Vice President, Co-head— Corporate Sector Ratings, ICRA

Sujay Shetty, Leader Pharma Life Sciences, PwC India

Dheeraj Aggarwal, CFO, Venus Remedies

Subhanu Saxena, Chief Executive Officer, Cipla

To conclude, post DPCO 2013, patients may spend less on medicines as the new policy underlines affordability of medines. On other hand, it is likely to hit the bottom lines of both domestic and MNC pharma companies and could even harm industry. Companies with sizable revenues from the US market will not feel the pinch as much. In the long run, government needs to find a better compromise between price and access to medicines.

(With inputs from Shalini Gupta)

u.sharma@expressindia.com

Comments (0)
Add Comment